COMPASS Pathways plc (CMPS)
$11.53-3.92%Close
SELLCRISIS · day 13
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.6B
- Beta
- 2.56
- P/E (TTM)
- -2.08
- Short % float
- 16.79%
- Days to cover
- 5.9
- SI change
- +11.8%
- 1W
- -0.60%
- 1M
- -19.65%
- vs SPY 1W
- -1.03%
- vs SPY 1M
- -21.71%
Industry peers
FMP comparable companies · ranked by market cap
- PRAXSELLPraxis Precision Medicines, Inc.$7.2BCRISISQ 11$259.86-3.26%
- DFTXSELLDefinium Therapeutics, Inc.$4.9BBEARQ 26$36.90-4.61%
- ACADSELLAcadia Pharmaceuticals Inc.$3.4BCRISISQ 18$19.78-1.87%
- DNLISELLDenali Therapeutics Inc.$3.1BCRISISQ 8$19.45-2.57%
- HRMYSELLHarmony Biosciences Holdings, Inc.$2.3BBEARQ 0$40.28-5.09%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.5BCRISISQ 25$30.65-1.63%
- GHRSSELLGH Research PLC$1.4BCRISISQ 15$21.11-5.16%
- LBRXSELLLB Pharmaceuticals Inc Common Stock$1.1BCRISISQ 78$37.22-3.47%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on CMPS?
- LOPJLB’s latest quantitative signal on COMPASS Pathways plc (CMPS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CMPS in?
- COMPASS Pathways plc (CMPS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does COMPASS Pathways plc (CMPS) do?
- COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is curre…